Regulation of the Low-Density Lipoprotein Receptor-Related Protein LRP6 and Its Association With Disease: Wnt/β-Catenin Signaling and Beyond
Wonyoung Jeong, Eek-Hoon Jho, Wonyoung Jeong, Eek-Hoon Jho
Abstract
Wnt signaling plays crucial roles in development and tissue homeostasis, and its dysregulation leads to various diseases, notably cancer. Wnt/β-catenin signaling is initiated when the glycoprotein Wnt binds to and forms a ternary complex with the Frizzled and low-density lipoprotein receptor-related protein 5/6 (LRP5/6). Despite being identified as a Wnt co-receptor over 20 years ago, the molecular mechanisms governing how LRP6 senses Wnt and transduces downstream signaling cascades are still being deciphered. Due to its role as one of the main Wnt signaling components, the dysregulation or mutation of LRP6 is implicated in several diseases such as cancer, neurodegeneration, metabolic syndrome and skeletal disease. Herein, we will review how LRP6 is activated by Wnt stimulation and explore the various regulatory mechanisms involved. The participation of LRP6 in other signaling pathways will also be discussed. Finally, the relationship between LRP6 dysregulation and disease will be examined in detail.
Keywords: LRP6; Wnt; cancer; metabolism; signaling.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Copyright © 2021 Jeong and Jho.
Figures
References
- Abe T., Zhou P., Jackman K., Capone C., Casolla B., Hochrainer K., et al. (2013). Lipoprotein receptor-related protein-6 protects the brain from ischemic injury. Stroke 44 2284–2291. 10.1161/strokeaha.113.001320
- Aberle H., Bauer A., Stappert J., Kispert A., Kemler R. (1997). Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16 3797–3804. 10.1093/emboj/16.13.3797
- Abrami L., Kunz B., Iacovache I., van der Goot F. G. (2008). Palmitoylation and ubiquitination regulate exit of the Wnt signaling protein LRP6 from the endoplasmic reticulum. Proc. Natl. Acad. Sci. U.S.A. 105 5384–5389. 10.1073/pnas.0710389105
- Acebron S. P., Niehrs C. (2016). β-catenin-independent roles of Wnt/LRP6 signaling. Trends Cell Biol. 26 956–967. 10.1016/j.tcb.2016.07.009
- Acebron S. P., Karaulanov E., Berger B. S., Huang Y. L., Niehrs C. (2014). Mitotic wnt signaling promotes protein stabilization and regulates cell size. Mol. Cell 54 663–674. 10.1016/j.molcel.2014.04.014
- Agajanian M. J., Walker M. P., Axtman A. D., Ruela-de-Sousa R. R., Serafin D. S., Rabinowitz A. D., et al. (2019). WNT activates the AAK1 kinase to promote clathrin-mediated endocytosis of LRP6 and establish a negative feedback loop. Cell Rep. 26 79–93.e8. 10.1016/j.celrep.2018.12.023
- Alarcón M. A., Medina M. A., Hu Q., Avila M. E., Bustos B. I., Pérez-Palma E., et al. (2013). A novel functional low-density lipoprotein receptor-related protein 6 gene alternative splice variant is associated with Alzheimer’s disease. Neurobiol. Aging 34 e1709–e1718. 10.1016/j.neurobiolaging.2012.11.004
- Avila M. E., Sepúlveda F. J., Burgos C. F., Moraga-Cid G., Parodi J., Moon R. T., et al. (2010). Canonical Wnt3a modulates intracellular calcium and enhances excitatory neurotransmission in hippocampal neurons. J. Biol. Chem. 285 18939–18947. 10.1074/jbc.M110.103028
- Azzolin L., Panciera T., Soligo S., Enzo E., Bicciato S., Dupont S., et al. (2014). YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 158 157–170. 10.1016/j.cell.2014.06.013
- Babij P., Zhao W., Small C., Kharode Y., Yaworsky P. J., Bouxsein M. L., et al. (2003). High bone mass in mice expressing a mutant LRP5 gene. J. Bone Miner. Res. 18 960–974. 10.1359/jbmr.2003.18.6.960
- Bafico A., Liu G., Yaniv A., Gazit A., Aaronson S. A. (2001). Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat. Cell Biol. 3 683–686. 10.1038/35083081
- Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., et al. (2001). Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10 537–543. 10.1093/hmg/10.5.537
- Berendsen A. D., Fisher L. W., Kilts T. M., Owens R. T., Robey P. G., Gutkind J. S., et al. (2011). Modulation of canonical Wnt signaling by the extracellular matrix component biglycan. Proc. Natl. Acad. Sci. U.S.A. 108 17022–17027. 10.1073/pnas.1110629108
- Berger B. S., Acebron S. P., Herbst J., Koch S., Niehrs C. (2017). Parkinson’s disease-associated receptor GPR37 is an ER chaperone for LRP6. EMBO Rep. 18 712–725. 10.15252/embr.201643585
- Berwick D. C., Harvey K. (2012). LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6. Hum. Mol. Genet. 21 4966–4979. 10.1093/hmg/dds342
- Bilic J., Huang Y. L., Davidson G., Zimmermann T., Cruciat C. M., Bienz M., et al. (2007). Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science 316 1619–1622. 10.1126/science.1137065
- Bryja V., Andersson E. R., Schambony A., Esner M., Bryjová L., Biris K. K., et al. (2009). The extracellular domain of Lrp5/6 inhibits noncanonical Wnt signaling in vivo. Mol. Biol. Cell 20 924–936. 10.1091/mbc.e08-07-0711
- Bugter J. M., Fenderico N., Maurice M. M. (2021). Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat. Rev. Cancer 21 5–21. 10.1038/s41568-020-00307-z
- Carmon K. S., Gong X., Lin Q., Thomas A., Liu Q. (2011). R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. Proc. Natl. Acad. Sci. U.S.A. 108 11452–11457. 10.1073/pnas.1106083108
- Červenka I., Wolf J., Mašek J., Krejci P., Wilcox W. R., Kozubík A., et al. (2011). Mitogen-activated protein kinases promote WNT/beta-catenin signaling via phosphorylation of LRP6. Mol. Cell. Biol. 31 179–189. 10.1128/mcb.00550-10
- Chen J., Rajasekaran M., Xia H., Kong S. N., Deivasigamani A., Sekar K., et al. (2018). CDK1-mediated BCL9 phosphorylation inhibits clathrin to promote mitotic Wnt signalling. EMBO J. 37:e99395. 10.15252/embj.201899395
- Chen M., Philipp M., Wang J., Premont R. T., Garrison T. R., Caron M. G., et al. (2009). G Protein-coupled receptor kinases phosphorylate LRP6 in the Wnt pathway. J. Biol. Chem. 284 35040–35048. 10.1074/jbc.M109.047456
- Chen Q., Su Y., Wesslowski J., Hagemann A. I., Ramialison M., Wittbrodt J., et al. (2014). Tyrosine phosphorylation of LRP6 by Src and Fer inhibits Wnt/β-catenin signalling. EMBO Rep. 15 1254–1267. 10.15252/embr.201439644
- Cheng Z., Biechele T., Wei Z., Morrone S., Moon R. T., Wang L., et al. (2011). Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat. Struct. Mol. Biol. 18 1204–1210. 10.1038/nsmb.2139
- Colozza G., Jami-Alahmadi Y., Dsouza A., Tejeda-Muñoz N., Albrecht L. V., Sosa E. A., et al. (2020). Wnt-inducible Lrp6-APEX2 interacting proteins identify ESCRT machinery and Trk-fused gene as components of the Wnt signaling pathway. Sci. Rep. 10:21555. 10.1038/s41598-020-78019-5
- Cselenyi C. S., Jernigan K. K., Tahinci E., Thorne C. A., Lee L. A., Lee E. (2008). LRP6 transduces a canonical Wnt signal independently of Axin degradation by inhibiting GSK3’s phosphorylation of beta-catenin. Proc. Natl. Acad. Sci. U.S.A. 105 8032–8037. 10.1073/pnas.0803025105
- Davidson G., Shen J., Huang Y. L., Su Y., Karaulanov E., Bartscherer K., et al. (2009). Cell cycle control of wnt receptor activation. Dev. Cell 17 788–799. 10.1016/j.devcel.2009.11.006
- Davidson G., Wu W., Shen J., Bilic J., Fenger U., Stannek P., et al. (2005). Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature 438 867–872. 10.1038/nature04170
- De Ferrari G. V., Papassotiropoulos A., Biechele T., Wavrant De-Vrieze F., Avila M. E., Major M. B., et al. (2007). Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 104 9434–9439. 10.1073/pnas.0603523104
- Demir K., Kirsch N., Beretta C. A., Erdmann G., Ingelfinger D., Moro E., et al. (2013). RAB8B is required for activity and caveolar endocytosis of LRP6. Cell Rep. 4 1224–1234. 10.1016/j.celrep.2013.08.008
- Ding Y., Colozza G., Sosa E. A., Moriyama Y., Rundle S., Salwinski L., et al. (2018). Bighead is a Wnt antagonist secreted by the Xenopus Spemann organizer that promotes Lrp6 endocytosis. Proc. Natl. Acad. Sci. U.S.A. 115 E9135–E9144. 10.1073/pnas.1812117115
- Dong Y., Zhang Y., Kang W., Wang G., Chen H., Higashimori A., et al. (2019). VSTM2A suppresses colorectal cancer and antagonizes Wnt signaling receptor LRP6. Theranostics 9 6517–6531. 10.7150/thno.34989
- Elliott C., Rojo A. I., Ribe E., Broadstock M., Xia W., Morin P., et al. (2018). A role for APP in Wnt signalling links synapse loss with β-amyloid production. Transl. Psychiatry 8:179. 10.1038/s41398-018-0231-6
- Ettenberg S. A., Charlat O., Daley M. P., Liu S., Vincent K. J., Stuart D. D., et al. (2010). Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc. Natl. Acad. Sci. U.S.A. 107 15473–15478. 10.1073/pnas.1007428107
- Ferrari N., Ranftl R., Chicherova I., Slaven N. D., Moeendarbary E., Farrugia A. J., et al. (2019). Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. Nat. Commun. 10:130. 10.1038/s41467-018-07987-0
- Gan L., Cookson M. R., Petrucelli L., La Spada A. R. (2018). Converging pathways in neurodegeneration, from genetics to mechanisms. Nat. Neurosci. 21 1300–1309. 10.1038/s41593-018-0237-7
- Go G. W., Srivastava R., Hernandez-Ono A., Gang G., Smith S. B., Booth C. J., et al. (2014). The combined hyperlipidemia caused by impaired Wnt-LRP6 signaling is reversed by Wnt3a rescue. Cell Metab. 19 209–220. 10.1016/j.cmet.2013.11.023
- Gong Y., Slee R. B., Fukai N., Rawadi G., Roman-Roman S., Reginato A. M., et al. (2001). LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 513–523. 10.1016/s0092-8674(01)00571-2
- Greten F. R., Grivennikov S. I. (2019). Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51 27–41. 10.1016/j.immuni.2019.06.025
- Grumolato L., Liu G., Mong P., Mudbhary R., Biswas R., Arroyave R., et al. (2010). Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev. 24 2517–2530. 10.1101/gad.1957710
- Hao H. X., Xie Y., Zhang Y., Charlat O., Oster E., Avello M., et al. (2012). ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 485 195–200. 10.1038/nature11019
- Holmen S. L., Giambernardi T. A., Zylstra C. R., Buckner-Berghuis B. D., Resau J. H., Hess J. F., et al. (2004). Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J. Bone Miner. Res. 19 2033–2040. 10.1359/jbmr.040907
- Hong S., Feng L., Yang Y., Jiang H., Hou X., Guo P., et al. (2020). In situ fucosylation of the Wnt co-receptor LRP6 increases its endocytosis and reduces Wnt/β-catenin signaling. Cell Chem. Biol. 27 1140–1150.e4. 10.1016/j.chembiol.2020.06.015
- Hong Y., Manoharan I., Suryawanshi A., Shanmugam A., Swafford D., Ahmad S., et al. (2016). Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity. Oncoimmunology 5:e1115941. 10.1080/2162402x.2015.1115941
- Hsieh J. C., Lee L., Zhang L., Wefer S., Brown K., DeRossi C., et al. (2003). Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity. Cell 112 355–367. 10.1016/s0092-8674(03)00045-x
- Jeong W., Kim S., Lee U., Zhong Z. A., Savitsky M., Kwon H., et al. (2020). LDL receptor-related protein LRP6 senses nutrient levels and regulates Hippo signaling. EMBO Rep. 21:e50103. 10.15252/embr.202050103
- Jernigan K. K., Cselenyi C. S., Thorne C. A., Hanson A. J., Tahinci E., Hajicek N., et al. (2010). Gbetagamma activates GSK3 to promote LRP6-mediated beta-catenin transcriptional activity. Sci. Signal. 3:ra37. 10.1126/scisignal.2000647
- Jia Q., Bu Y., Wang Z., Chen B., Zhang Q., Yu S., et al. (2017). Maintenance of stemness is associated with the interation of LRP6 and heparin-binding protein CCN2 autocrined by hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 36:117. 10.1186/s13046-017-0576-3
- Jiang X., Charlat O., Zamponi R., Yang Y., Cong F. (2015). Dishevelled promotes Wnt receptor degradation through recruitment of ZNRF3/RNF43 E3 ubiquitin ligases. Mol. Cell 58 522–533. 10.1016/j.molcel.2015.03.015
- Jiang Y., He X., Howe P. H. (2012). Disabled-2 (Dab2) inhibits Wnt/β-catenin signalling by binding LRP6 and promoting its internalization through clathrin. EMBO J. 31 2336–2349. 10.1038/emboj.2012.83
- Joeng K. S., Schumacher C. A., Zylstra-Diegel C. R., Long F., Williams B. O. (2011). Lrp5 and Lrp6 redundantly control skeletal development in the mouse embryo. Dev. Biol. 359 222–229. 10.1016/j.ydbio.2011.08.020
- Joiner D. M., Ke J., Zhong Z., Xu H. E., Williams B. O. (2013). LRP5 and LRP6 in development and disease. Trends Endocrinol. Metab. 24 31–39. 10.1016/j.tem.2012.10.003
- Jung H., Lee S. K., Jho E. H. (2011). Mest/Peg1 inhibits Wnt signalling through regulation of LRP6 glycosylation. Biochem. J. 436 263–269. 10.1042/bj20101512
- Kagermeier-Schenk B., Wehner D., Ozhan-Kizil G., Yamamoto H., Li J., Kirchner K., et al. (2011). Waif1/5T4 inhibits Wnt/β-catenin signaling and activates noncanonical Wnt pathways by modifying LRP6 subcellular localization. Dev. Cell 21 1129–1143. 10.1016/j.devcel.2011.10.015
- Keramati A. R., Singh R., Lin A., Faramarzi S., Ye Z. J., Mane S., et al. (2011). Wild-type LRP6 inhibits, whereas atherosclerosis-linked LRP6R611C increases PDGF-dependent vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 108 1914–1918. 10.1073/pnas.1019443108
- Khan Z., Vijayakumar S., de la Torre T. V., Rotolo S., Bafico A. (2007). Analysis of endogenous LRP6 function reveals a novel feedback mechanism by which Wnt negatively regulates its receptor. Mol. Cell. Biol. 27 7291–7301. 10.1128/mcb.00773-07
- Kikuchi A., Yamamoto H., Sato A. (2009). Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol. 19 119–129. 10.1016/j.tcb.2009.01.003
- Kim I., Pan W., Jones S. A., Zhang Y., Zhuang X., Wu D. (2013). Clathrin and AP2 are required for PtdIns(4,5)P2-mediated formation of LRP6 signalosomes. J. Cell Biol. 200 419–428. 10.1083/jcb.201206096
- Kim M., Kim S., Lee S. H., Kim W., Sohn M. J., Kim H. S., et al. (2016). Merlin inhibits Wnt/β-catenin signaling by blocking LRP6 phosphorylation. Cell Death Differ. 23 1638–1647. 10.1038/cdd.2016.54
- Kim W., Kim S. Y., Kim T., Kim M., Bae D. J., Choi H. I., et al. (2013). ADP-ribosylation factors 1 and 6 regulate Wnt/β-catenin signaling via control of LRP6 phosphorylation. Oncogene 32 3390–3396. 10.1038/onc.2012.373
- Kirsch N., Chang L. S., Koch S., Glinka A., Dolde C., Colozza G., et al. (2017). Angiopoietin-like 4 Is a Wnt Signaling Antagonist that Promotes LRP6 Turnover. Dev. Cell 43 71.e–82.e. 10.1016/j.devcel.2017.09.011
- Kitagawa M., Hatakeyama S., Shirane M., Matsumoto M., Ishida N., Hattori K., et al. (1999). An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J. 18 2401–2410. 10.1093/emboj/18.9.2401
- Koo B. K., Spit M., Jordens I., Low T. Y., Stange D. E., van de Wetering M., et al. (2012). Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488 665–669. 10.1038/nature11308
- Koslowski M. J., Teltschik Z., Beisner J., Schaeffeler E., Wang G., Kübler I., et al. (2012). Association of a functional variant in the Wnt co-receptor LRP6 with early onset ileal Crohn’s disease. PLoS Genet. 8:e1002523. 10.1371/journal.pgen.1002523
- Krejci P., Aklian A., Kaucka M., Sevcikova E., Prochazkova J., Masek J. K., et al. (2012). Receptor tyrosine kinases activate canonical WNT/β-catenin signaling via MAP kinase/LRP6 pathway and direct β-catenin phosphorylation. PLoS One 7:e35826. 10.1371/journal.pone.0035826
- Kumari U., Tan E. K. (2009). LRRK2 in Parkinson’s disease: genetic and clinical studies from patients. FEBS J. 276 6455–6463. 10.1111/j.1742-4658.2009.07344.x
- Lai K. K. Y., Kweon S. M., Chi F., Hwang E., Kabe Y., Higashiyama R., et al. (2017). Stearoyl-CoA desaturase promotes liver fibrosis and tumor development in mice via a Wnt positive-signaling loop by stabilization of low-density lipoprotein-receptor-related proteins 5 and 6. Gastroenterology 152 1477–1491. 10.1053/j.gastro.2017.01.021
- Landskroner-Eiger S., Qiu C., Perrotta P., Siragusa M., Lee M. Y., Ulrich V., et al. (2015). Endothelial miR-17∼92 cluster negatively regulates arteriogenesis via miRNA-19 repression of WNT signaling. Proc. Natl. Acad. Sci. U.S.A. 112 12812–12817. 10.1073/pnas.1507094112
- Lemieux E., Cagnol S., Beaudry K., Carrier J., Rivard N. (2015). Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene 34 4914–4927. 10.1038/onc.2014.416
- Li C., Wang W., Xie L., Luo X., Cao X., Wan M. (2016). Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression. Ann. N. Y. Acad. Sci. 1364 62–73. 10.1111/nyas.12750
- Li C., Xing Q., Yu B., Xie H., Wang W., Shi C., et al. (2013). Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH. J. Bone Miner. Res. 28 2094–2108. 10.1002/jbmr.1962
- Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., et al. (2005). Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280 19883–19887. 10.1074/jbc.M413274200
- Li Y., Lu W., He X., Schwartz A. L., Bu G. (2004). LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution. Oncogene 23 9129–9135. 10.1038/sj.onc.1208123
- Lian G., Dettenhofer M., Lu J., Downing M., Chenn A., Wong T., et al. (2016). Filamin A- and formin 2-dependent endocytosis regulates proliferation via the canonical Wnt pathway. Development 143 4509–4520. 10.1242/dev.139295
- Liang J., Fu Y., Cruciat C. M., Jia S., Wang Y., Tong Z., et al. (2011). Transmembrane protein 198 promotes LRP6 phosphorylation and Wnt signaling activation. Mol. Cell. Biol. 31 2577–2590. 10.1128/mcb.05103-11
- Lin Y., Jian Z., Jin H., Wei X., Zou X., Guan R., et al. (2020). Long non-coding RNA DLGAP1-AS1 facilitates tumorigenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via the feedback loop of miR-26a/b-5p/IL-6/JAK2/STAT3 and Wnt/β-catenin pathway. Cell Death Dis. 11:34. 10.1038/s41419-019-2188-7
- Lindvall C., Zylstra C. R., Evans N., West R. A., Dykema K., Furge K. A., et al. (2009). The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development. PLoS One 4:e5813. 10.1371/journal.pone.0005813
- Liu B., Staron M., Hong F., Wu B. X., Sun S., Morales C., et al. (2013). Essential roles of grp94 in gut homeostasis via chaperoning canonical Wnt pathway. Proc. Natl. Acad. Sci. U.S.A. 110 6877–6882. 10.1073/pnas.1302933110
- Liu C. C., Prior J., Piwnica-Worms D., Bu G. (2010). LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc. Natl. Acad. Sci. U.S.A. 107 5136–5141. 10.1073/pnas.0911220107
- Liu C. C., Tsai C. W., Deak F., Rogers J., Penuliar M., Sung Y. M., et al. (2014). Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer’s disease. Neuron 84 63–77. 10.1016/j.neuron.2014.08.048
- Liu C., Li Y., Semenov M., Han C., Baeg G. H., Tan Y., et al. (2002). Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108 837–847. 10.1016/s0092-8674(02)00685-2
- Liu G., Bafico A., Harris V. K., Aaronson S. A. (2003). A novel mechanism for Wnt activation of canonical signaling through the LRP6 receptor. Mol. Cell. Biol. 23 5825–5835. 10.1128/mcb.23.16.5825-5835.2003
- Liu W., Mani S., Davis N. R., Sarrafzadegan N., Kavathas P. B., Mani A. (2008). Mutation in EGFP domain of LDL receptor-related protein 6 impairs cellular LDL clearance. Circ. Res. 103 1280–1288. 10.1161/circresaha.108.183863
- Liu W., Xing F., Iiizumi-Gairani M., Okuda H., Watabe M., Pai S. K., et al. (2012). N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol. Med. 4 93–108. 10.1002/emmm.201100190
- Lu H., Ma J., Yang Y., Shi W., Luo L. (2013). EpCAM is an endoderm-specific Wnt derepressor that licenses hepatic development. Dev. Cell 24 543–553. 10.1016/j.devcel.2013.01.021
- MacDonald B. T., He X. (2012). Frizzled and LRP5/6 receptors for Wnt/β-catenin signaling. Cold Spring Harb. Perspect. Biol. 4:a007880. 10.1101/cshperspect.a007880
- MacDonald B. T., Tamai K., He X. (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17 9–26. 10.1016/j.devcel.2009.06.016
- Madan B., Walker M. P., Young R., Quick L., Orgel K. A., Ryan M., et al. (2016). USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds. Proc. Natl. Acad. Sci. U.S.A. 113 E2945–E2954. 10.1073/pnas.1605691113
- Mani A., Radhakrishnan J., Wang H., Mani A., Mani M. A., Nelson-Williams C., et al. (2007). LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315 1278–1282. 10.1126/science.1136370
- Mao B., Wu W., Davidson G., Marhold J., Li M., Mechler B. M., et al. (2002). Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417 664–667. 10.1038/nature756
- Mao B., Wu W., Li Y., Hoppe D., Stannek P., Glinka A., et al. (2001). LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411 321–325. 10.1038/35077108
- Mao J., Wang J., Liu B., Pan W., Farr G. H., III, Flynn C., et al. (2001). Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol. Cell 7 801–809. 10.1016/s1097-2765(01)00224-6
- Meng Z., Moroishi T., Guan K. L. (2016). Mechanisms of Hippo pathway regulation. Genes Dev. 30 1–17. 10.1101/gad.274027.115
- Metcalfe C., Mendoza-Topaz C., Mieszczanek J., Bienz M. (2010). Stability elements in the LRP6 cytoplasmic tail confer efficient signalling upon DIX-dependent polymerization. J. Cell Sci. 123(Pt 9) 1588–1599. 10.1242/jcs.067546
- Nava P., Koch S., Laukoetter M. G., Lee W. Y., Kolegraff K., Capaldo C. T., et al. (2010). Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways. Immunity 32 392–402. 10.1016/j.immuni.2010.03.001
- Nusse R., Clevers H. (2017). Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169 985–999. 10.1016/j.cell.2017.05.016
- Özhan G., Sezgin E., Wehner D., Pfister A. S., Kühl S. J., Kagermeier-Schenk B., et al. (2013). Lypd6 enhances Wnt/β-catenin signaling by promoting Lrp6 phosphorylation in raft plasma membrane domains. Dev. Cell 26 331–345. 10.1016/j.devcel.2013.07.020
- Pan D. (2010). The hippo signaling pathway in development and cancer. Dev. Cell 19 491–505. 10.1016/j.devcel.2010.09.011
- Pan W., Choi S. C., Wang H., Qin Y., Volpicelli-Daley L., Swan L., et al. (2008). Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation. Science 321 1350–1353. 10.1126/science.1160741
- Park K., Lee K., Zhang B., Zhou T., He X., Gao G., et al. (2011). Identification of a novel inhibitor of the canonical Wnt pathway. Mol. Cell. Biol. 31 3038–3051. 10.1128/mcb.01211-10
- Perrody E., Abrami L., Feldman M., Kunz B., Urbé S., van der Goot F. G. (2016). Ubiquitin-dependent folding of the Wnt signaling coreceptor LRP6. Elife 5:e19083. 10.7554/eLife.19083
- Pinson K. I., Brennan J., Monkley S., Avery B. J., Skarnes W. C. (2000). An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407 535–538. 10.1038/35035124
- Raines E. W. (2004). PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 15 237–254. 10.1016/j.cytogfr.2004.03.004
- Regard J. B., Zhong Z., Williams B. O., Yang Y. (2012). Wnt signaling in bone development and disease: making stronger bone with Wnts. Cold Spring Harb. Perspect. Biol. 4:a007997. 10.1101/cshperspect.a007997
- Ren D. N., Chen J., Li Z., Yan H., Yin Y., Wo D., et al. (2015). LRP5/6 directly bind to Frizzled and prevent Frizzled-regulated tumour metastasis. Nat. Commun. 6:6906. 10.1038/ncomms7906
- Rochlani Y., Pothineni N. V., Kovelamudi S., Mehta J. L. (2017). Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther. Adv. Cardiovasc. Dis. 11 215–225. 10.1177/1753944717711379
- Saito-Diaz K., Benchabane H., Tiwari A., Tian A., Li B., Thompson J. J., et al. (2018). APC inhibits ligand-independent Wnt signaling by the clathrin endocytic pathway. Dev. Cell 44 566–581.e8. 10.1016/j.devcel.2018.02.013
- Sakane H., Yamamoto H., Kikuchi A. (2010). LRP6 is internalized by Dkk1 to suppress its phosphorylation in the lipid raft and is recycled for reuse. J. Cell Sci. 123(Pt 3) 360–368. 10.1242/jcs.058008
- Sato A., Yamamoto H., Sakane H., Koyama H., Kikuchi A. (2010). Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J. 29 41–54. 10.1038/emboj.2009.322
- Schmitt M., Metzger M., Gradl D., Davidson G., Orian-Rousseau V. (2015). CD44 functions in Wnt signaling by regulating LRP6 localization and activation. Cell Death Differ. 22 677–689. 10.1038/cdd.2014.156
- Semënov M. V., Tamai K., Brott B. K., Kühl M., Sokol S., He X. (2001). Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr. Biol. 11 951–961. 10.1016/s0960-9822(01)00290-1
- Semënov M., Tamai K., He X. (2005). SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 280 26770–26775. 10.1074/jbc.M504308200
- Sezgin E., Levental I., Mayor S., Eggeling C. (2017). The mystery of membrane organization: composition, regulation and roles of lipid rafts. Nat. Rev. Mol. Cell Biol. 18 361–374. 10.1038/nrm.2017.16
- Sharma K., Choi S. Y., Zhang Y., Nieland T. J., Long S., Li M., et al. (2013). High-throughput genetic screen for synaptogenic factors: identification of LRP6 as critical for excitatory synapse development. Cell Rep. 5 1330–1341. 10.1016/j.celrep.2013.11.008
- Singh R., De Aguiar R. B., Naik S., Mani S., Ostadsharif K., Wencker D., et al. (2013a). LRP6 enhances glucose metabolism by promoting TCF7L2-dependent insulin receptor expression and IGF receptor stabilization in humans. Cell Metab. 17 197–209. 10.1016/j.cmet.2013.01.009
- Singh R., Smith E., Fathzadeh M., Liu W., Go G. W., Subrahmanyan L., et al. (2013b). Rare nonconservative LRP6 mutations are associated with metabolic syndrome. Hum. Mutat. 34 1221–1225. 10.1002/humu.22360
- Srivastava R., Zhang J., Go G. W., Narayanan A., Nottoli T. P., Mani A. (2015). Impaired LRP6-TCF7L2 activity enhances smooth muscle cell plasticity and causes coronary artery disease. Cell Rep. 13 746–759. 10.1016/j.celrep.2015.09.028
- Swiatek W., Kang H., Garcia B. A., Shabanowitz J., Coombs G. S., Hunt D. F., et al. (2006). Negative regulation of LRP6 function by casein kinase I epsilon phosphorylation. J. Biol. Chem. 281 12233–12241. 10.1074/jbc.M510580200
- Taelman V. F., Dobrowolski R., Plouhinec J. L., Fuentealba L. C., Vorwald P. P., Gumper I., et al. (2010). Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 143 1136–1148. 10.1016/j.cell.2010.11.034
- Tahir S. A., Yang G., Goltsov A., Song K. D., Ren C., Wang J., et al. (2013). Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res. 73 1900–1911. 10.1158/0008-5472.can-12-3040
- Tamai K., Semenov M., Kato Y., Spokony R., Liu C., Katsuyama Y., et al. (2000). LDL-receptor-related proteins in Wnt signal transduction. Nature 407 530–535. 10.1038/35035117
- Tamai K., Zeng X., Liu C., Zhang X., Harada Y., Chang Z., et al. (2004). A mechanism for Wnt coreceptor activation. Mol. Cell 13 149–156. 10.1016/s1097-2765(03)00484-2
- Tanneberger K., Pfister A. S., Brauburger K., Schneikert J., Hadjihannas M. V., Kriz V., et al. (2011). Amer1/WTX couples Wnt-induced formation of PtdIns(4,5)P2 to LRP6 phosphorylation. EMBO J. 30 1433–1443. 10.1038/emboj.2011.28
- Tung E. K., Wong B. Y., Yau T. O., Ng I. O. (2012). Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion. PLoS One 7:e36565. 10.1371/journal.pone.0036565
- Wan M., Li J., Herbst K., Zhang J., Yu B., Wu X., et al. (2011). LRP6 mediates cAMP generation by G protein-coupled receptors through regulating the membrane targeting of Gα(s). Sci. Signal. 4:ra15. 10.1126/scisignal.2001464
- Wan M., Yang C., Li J., Wu X., Yuan H., Ma H., et al. (2008). Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 22 2968–2979. 10.1101/gad.1702708
- Wang H., He L., Ma F., Regan M. M., Balk S. P., Richardson A. L., et al. (2013). SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer. J. Biol. Chem. 288 6478–6487. 10.1074/jbc.M112.419184
- Wang L., Chai Y., Li C., Liu H., Su W., Liu X., et al. (2018). Oxidized phospholipids are ligands for LRP6. Bone Res. 6:22. 10.1038/s41413-018-0023-x
- Wang X., Jia Y., Fei C., Song X., Li L. (2016). Activation/proliferation-associated protein 2 (Caprin-2) positively regulates CDK14/cyclin Y-mediated lipoprotein receptor-related protein 5 and 6 (LRP5/6) constitutive phosphorylation. J. Biol. Chem. 291 26427–26434. 10.1074/jbc.M116.744607
- Wang Y., Yin C., Chen Z., Li Y., Zou Y., Wang X., et al. (2020). Cardiac-specific LRP6 knockout induces lipid accumulation through Drp1/CPT1b pathway in adult mice. Cell Tissue Res. 380 143–153. 10.1007/s00441-019-03126-3
- Wehrli M., Dougan S. T., Caldwell K., O’Keefe L., Schwartz S., Vaizel-Ohayon D., et al. (2000). arrow encodes an LDL-receptor-related protein essential for Wingless signalling. Nature 407 527–530. 10.1038/35035110
- Wei Q., Yokota C., Semenov M. V., Doble B., Woodgett J., He X. (2007). R-spondin1 is a high affinity ligand for LRP6 and induces LRP6 phosphorylation and beta-catenin signaling. J. Biol. Chem. 282 15903–15911. 10.1074/jbc.M701927200
- Wu G., Huang H., Garcia Abreu J., He X. (2009). Inhibition of GSK3 phosphorylation of beta-catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6. PLoS One 4:e4926. 10.1371/journal.pone.0004926
- Wu Z., Wei D., Gao W., Xu Y., Hu Z., Ma Z., et al. (2015). TPO-induced metabolic reprogramming drives liver metastasis of colorectal cancer CD110+ tumor-initiating cells. Cell Stem Cell 17 47–59. 10.1016/j.stem.2015.05.016
- Xia Z., Wu S., Wei X., Liao Y., Yi P., Liu Y., et al. (2019). Hypoxic ER stress suppresses β-catenin expression and promotes cooperation between the transcription factors XBP1 and HIF1α for cell survival. J. Biol. Chem. 294 13811–13821. 10.1074/jbc.RA119.008353
- Yamamoto H., Komekado H., Kikuchi A. (2006). Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. Dev. Cell 11 213–223. 10.1016/j.devcel.2006.07.003
- Yamamoto H., Sakane H., Yamamoto H., Michiue T., Kikuchi A. (2008). Wnt3a and Dkk1 regulate distinct internalization pathways of LRP6 to tune the activation of beta-catenin signaling. Dev. Cell 15 37–48. 10.1016/j.devcel.2008.04.015
- Ye Z. J., Go G. W., Singh R., Liu W., Keramati A. R., Mani A. (2012). LRP6 protein regulates low density lipoprotein (LDL) receptor-mediated LDL uptake. J. Biol. Chem. 287 1335–1344. 10.1074/jbc.M111.295287
- Yuan Y., Xie X., Jiang Y., Wei Z., Wang P., Chen F., et al. (2017). LRP6 is identified as a potential prognostic marker for oral squamous cell carcinoma via MALDI-IMS. Cell Death Dis. 8:e3035. 10.1038/cddis.2017.433
- Zeng X., Huang H., Tamai K., Zhang X., Harada Y., Yokota C., et al. (2008). Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 135 367–375. 10.1242/dev.013540
- Zeng X., Tamai K., Doble B., Li S., Huang H., Habas R., et al. (2005). A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438 873–877. 10.1038/nature04185
- Zhang J., Li Y., Liu Q., Lu W., Bu G. (2010). Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis. Oncogene 29 539–549. 10.1038/onc.2009.339
Source: PubMed